Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 216

1.

Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.

Danchin M, Kirkwood CD, Lee KJ, Bishop RF, Watts E, Justice FA, Clifford V, Cowley D, Buttery JP, Bines JE.

Vaccine. 2013 May 28;31(23):2610-6. doi: 10.1016/j.vaccine.2013.04.008.

PMID:
23597719
2.

Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial.

Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ, West A, Cowley D, Chen MY, Barnes GL, Justice F, Buttery JP, Carlin JB, Bishop RF, Taylor B, Kirkwood CD; RV3 Rotavirus Vaccine Program..

Lancet Infect Dis. 2015 Dec;15(12):1389-97. doi: 10.1016/S1473-3099(15)00227-3.

PMID:
26318715
3.

Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.

Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, Smolenov IV, Han HH; ROTA-054 Study Group..

Pediatr Infect Dis J. 2012 May;31(5):487-93. doi: 10.1097/INF.0b013e3182490a2c.

PMID:
22228231
4.

A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.

Dang DA, Nguyen VT, Vu DT, Nguyen TH, Nguyen DM, Yuhuan W, Baoming J, Nguyen DH, Le TL; Rotavin-M1 Vaccine Trial Group..

Vaccine. 2012 Apr 27;30 Suppl 1:A114-21. doi: 10.1016/j.vaccine.2011.07.118.

PMID:
22520120
5.

Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants.

Phua KB, Quak SH, Lee BW, Emmanuel SC, Goh P, Han HH, De Vos B, Bock HL.

J Infect Dis. 2005 Sep 1;192 Suppl 1:S6-S16.

PMID:
16088807
6.

Early phase II trial of human rotavirus vaccine candidate RV3.

Barnes GL, Lund JS, Mitchell SV, De Bruyn L, Piggford L, Smith AL, Furmedge J, Masendycz PJ, Bugg HC, Bogdanovic-Sakran N, Carlin JB, Bishop RF.

Vaccine. 2002 Jul 26;20(23-24):2950-6.

PMID:
12126907
7.

Immunogenicity of the pentavalent rotavirus vaccine in African infants.

Armah GE, Breiman RF, Tapia MD, Dallas MJ, Neuzil KM, Binka FN, Sow SO, Ojwando J, Ciarlet M, Steele AD.

Vaccine. 2012 Apr 27;30 Suppl 1:A86-93. doi: 10.1016/j.vaccine.2011.10.006.

PMID:
22520142
8.

Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.

Li RC, Li YP, Mo ZJ, Luo D, Huang T, Kong JL, Wang LH, Song NS, Liu A, Zhang H, Liao X, Karkada N, Han HH.

Hum Vaccin Immunother. 2013 Aug;9(8):1638-42. doi: 10.4161/hv.25076.

9.

A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial.

Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, Appaiahgari MB, Mishra A, Singh S, Vrati S; Rotavirus Vaccine Development Group..

J Infect Dis. 2009 Aug 1;200(3):421-9. doi: 10.1086/600104.

PMID:
19545211
10.

Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.

Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP, Cervantes Y, Costa Clemens S, Damaso S, Hardt K, De Vos B.

Pediatr Infect Dis J. 2005 Sep;24(9):807-16.

PMID:
16148848
11.

Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.

Shin S, Anh DD, Zaman K, Yunus M, Mai le TP, Thiem VD, Azim T, Victor JC, Dallas MJ, Steele AD, Neuzil KM, Ciarlet M.

Vaccine. 2012 Apr 27;30 Suppl 1:A106-13. doi: 10.1016/j.vaccine.2011.11.091.

PMID:
22520119
12.

Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants.

Clements-Mann ML, Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M, Stephens I, Karron R, Deforest A, Kapikian AZ.

Vaccine. 2001 Sep 14;19(32):4676-84.

PMID:
11535316
13.

Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate.

Barnes GL, Lund JS, Adams L, Mora A, Mitchell SV, Caples A, Bishop RF.

J Paediatr Child Health. 1997 Aug;33(4):300-4.

PMID:
9323616
14.

Safety and immunogenicity of tetravalent rhesus-based rotavirus vaccine in Bangladesh.

Bresee JS, El Arifeen S, Azim T, Chakraborty J, Mounts AW, Podder G, Gentsch JR, Ward RL, Black R, Glass RI, Yunus M.

Pediatr Infect Dis J. 2001 Dec;20(12):1136-43.

PMID:
11740320
15.

Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants.

Vesikari T, Karvonen A, Bouckenooghe A, Suryakiran PV, Smolenov I, Han HH.

Vaccine. 2011 Mar 3;29(11):2079-84. doi: 10.1016/j.vaccine.2011.01.004.

PMID:
21238572
16.

Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine.

Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey JC, Fischer FH Jr, Innis BL, Rathfon H, Schuind A, De Vos B; North American Human Rotavirus Vaccine Study Group..

Pediatr Infect Dis J. 2005 Jun;24(6):481-8.

PMID:
15933555
17.

Neonatal administration of rhesus rotavirus tetravalent vaccine.

Vesikari T, Karvonen A, Forrest BD, Hoshino Y, Chanock RM, Kapikian AZ.

Pediatr Infect Dis J. 2006 Feb;25(2):118-22.

PMID:
16462287
18.

Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.

Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ, Laura D, Eiden JJ, Ivanoff N, Kaplan KM, Heaton P.

J Pediatr. 2004 Feb;144(2):184-90. Erratum in: J Pediatr. 2004 Apr;144(4):558.

PMID:
14760258
19.

Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.

Steele AD, Reynders J, Scholtz F, Bos P, de Beer MC, Tumbo J, Van der Merwe CF, Delem A, De Vos B.

J Infect Dis. 2010 Sep 1;202 Suppl:S93-100. doi: 10.1086/653550.

PMID:
20684724
20.

Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants.

Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J, Zepp F, Delem A, De Vos B.

Vaccine. 2004 Jul 29;22(21-22):2836-42.

PMID:
15246619

Supplemental Content

Support Center